Actinium Pharmaceuticals (NYSE:ATNM) Trading Down 5.4% – Should You Sell?

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s share price traded down 5.4% on Wednesday . The company traded as low as $1.21 and last traded at $1.22. 145,651 shares were traded during mid-day trading, an increase of 17% from the average session volume of 124,570 shares. The stock had previously closed at $1.29.

Actinium Pharmaceuticals Stock Performance

The stock has a market cap of $38.06 million, a P/E ratio of -0.88 and a beta of -0.30. The stock’s fifty day moving average is $1.42 and its 200 day moving average is $1.52.

Institutional Trading of Actinium Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. North Star Asset Management Inc. increased its stake in Actinium Pharmaceuticals by 100.0% in the second quarter. North Star Asset Management Inc. now owns 20,000 shares of the company’s stock valued at $28,000 after purchasing an additional 10,000 shares during the last quarter. Vanguard Group Inc. boosted its position in Actinium Pharmaceuticals by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock worth $2,215,000 after purchasing an additional 12,703 shares during the period. Mayport LLC purchased a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter valued at about $35,000. Bank of America Corp DE lifted its position in shares of Actinium Pharmaceuticals by 76.6% during the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Actinium Pharmaceuticals by 278.6% in the first quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock worth $102,000 after acquiring an additional 46,545 shares in the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.